TY - JOUR
T1 - The european hematology association roadmap for european hematology research
T2 - A consensus document
AU - EHA Roadmap for European Hematology Research
AU - Engert, Andreas
AU - Balduini, Carlo
AU - Brand, Anneke
AU - Coiffier, Bertrand
AU - Cordonnier, Catherine
AU - Döhner, Hartmut
AU - De Wit, Thom Duyvené
AU - Eichinger, Sabine
AU - Fibbe, Willem
AU - Green, Tony
AU - De Haas, Fleur
AU - Iolascon, Achille
AU - Jaffredo, Thierry
AU - Rodeghiero, Francesco
AU - Sall Es, Gilles
AU - Schuringa, Jan Jacob
AU - André, Marc
AU - Andre-Schmutz, Isabelle
AU - Bacigalupo, Andrea
AU - Bochud, Pierre Yves
AU - Den Boer, Monique
AU - Bonini, Chiara
AU - Camaschella, Clara
AU - Cant, Andrew
AU - Cappellini, Maria Domenica
AU - Cazzola, Mario
AU - Celso, Cristina Lo
AU - Dimopoulos, Meletios
AU - Douay, Luc
AU - Dzierzak, Elaine
AU - Einsele, Hermann
AU - Ferreri, Andrés
AU - De Franceschi, Lucia
AU - Gaulard, Philippe
AU - Gottgens, Berthold
AU - Greinacher, Andreas
AU - Gresele, Paolo
AU - Gribben, John
AU - De Haan, Gerald
AU - Hansen, John Bjarne
AU - Hochhaus, Andreas
AU - Kadir, Rezan
AU - Kaveri, Srini
AU - Kouskoff, Valerie
AU - Kühne, Thomas
AU - Kyrle, Paul
AU - Ljungman, Per
AU - Maschmeyer, Georg
AU - Méndez-Ferrer, Simón
AU - Oostendorp, Robert
N1 - Publisher Copyright:
© 2016 Ferrata Storti Foundation.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at ∈ European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better fu treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine ‘sections’ in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.
AB - The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at ∈ European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better fu treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine ‘sections’ in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.
UR - https://www.scopus.com/pages/publications/84981361090
U2 - 10.3324/haematol.2015.136739
DO - 10.3324/haematol.2015.136739
M3 - Article
C2 - 26819058
AN - SCOPUS:84981361090
SN - 0390-6078
VL - 101
SP - 115
EP - 208
JO - Haematologica
JF - Haematologica
IS - 2
ER -